Efficacy of administering at early stage of BCAA supplementation

Efficacy of administering at early stage of BCAA supplementation - Efficacy of administering at early stage of BCAA supplementation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002889

Enrollment

Registered

2009-12-14

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

compensated cirrhosis

Interventions

BCAA supplementation (BCAA3.2g) is taken 12 weeks continuously three times a day. Dietary intake of 12 weeks according to usual nourishment guidance

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Compensated cirrhosis 2. Serum albumin revel; 3.5-4.0mg/dL 3. Patients who give documentary informed consent voluntarily 4. Patient who fills all of the above-mentioned 1-3

Exclusion criteria

Exclusion criteria: 1. Decompensated cirrhosis 2. Patient with serious glucose intolerance 3. Patient who has allergy in element of AMINOFEEL 4. Patient who has infectious disease that becomes problem in clinical 5. Patient inappropriate for participating to this study decided by the attending physicians

Design outcomes

Primary

Measure	Time frame
75g oral glucose tolerance test, HOMA-IR (homeostasis model assessment-insulin resistance) and after 12 weeks from the beginning of the dairy branched-chain amino acid supplementation intake	—

Secondary

Measure	Time frame
Serum albumin revel, BTR, Zn, platelet, Quality of Life(SF-36) and Urinary 8-OHdG excretion after 12 weeks from the beginning of the dairy BCAA supplementation intake	—

Countries

Japan

Contacts

Public ContactMasaki Saito

Hyogo College of Medicine Division of Hepatobiliary and Pancreatic Diseases

he-jishu@hyo-med.ac.jp0798-45-6472

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026